Paul Fishkin, MD, Oncology, Peoria, IL, UnityPoint Health - Peoria

PaulA.S.FishkinMD

Oncology Peoria, IL

Hematologic Oncology

Illinois CancerCare

Dr. Fishkin is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fishkin's full profile

Already have an account?

Education & Training

  • Letterman Army Medical CenterFellowship, Hematology, 1987 - 1990
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 1984 - 1987
  • Creighton University School of Medicine
    Creighton University School of MedicineClass of 1984
  • Creighton UniversityB.A., 1980

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1993 - 2023
  • CA State Medical License
    CA State Medical License 1988 - 2021
  • OK State Medical License
    OK State Medical License 1985 - 1991
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic b...  
    Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA, Clin Breast Cancer, 1/1/2012
  • CD10 Detection by Flow Cytometry as a Prognostic Marker in de Novo Diffuse Large B-Cell Lymphoma  
    Siebert JD, Weeks LM, Sun J, Knost JA, Fishkin PAS, Thomas SP, Kugler JW, Am J Clin Path, 1/1/2002
  • Utility of flow cytometry immunophenotyping of fine needle aspiration/biopsy samples in the diagnosis and classification of lymphoma in a community hospital  
    Siebert JD, Weeks LM, List LW, Kugler JW, Knost JA, Fishkin PAS, Goergen MH, Am J Clin Pathol, 1/1/1999
  • Join now to see all

Abstracts/Posters

  • Evaluation of chemotherapy within last two weeks of life: Patterns of care
    Thomas SP, Rice MA, Ho TA, Heard B, Harper J, Fishkin PAS, ASCO Annual Meeting; J Clin Oncol, 1/1/2013
  • Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma
    Inwards DJ, Fishkin, P, LaPlant BR, Drake MT, Kurtin P, Nikcevich D, Wender D, Lair B, Witzig TE, ASH Annual Meeting, 1/1/2012
  • Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (N0189)
    Inwards DJ, Hillman DW, Fishkin PA, White WL, Morton RF, Dakhil SR, Nikcevich DA, Wender DB, Fitch RT, Kurtin PJ:, Proc Annu Meet Am Soc Clin Oncol, 1/1/2006
  • Join now to see all

Lectures

  • Clinical Careers in Hematology (Private Practice Careers) 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Career-Development Lunch Sessions: Clinical Careers in Hematology (Private Practice) 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • “Onco-Genetics of Cancer” Seminar 
    University of Illinois College of Medicine, Peoria, IL - 1/16/1998
  • Join now to see all

Professional Memberships

Hospital Affiliations